Skip to main content
Erschienen in: Neuroradiology 4/2016

21.01.2016 | Diagnostic Neuroradiology

Identifying the association between contrast enhancement pattern, surgical resection, and prognosis in anaplastic glioma patients

verfasst von: Yinyan Wang, Kai Wang, Jiangfei Wang, Shaowu Li, Jun Ma, Jianping Dai, Tao Jiang

Erschienen in: Neuroradiology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Contrast enhancement observable on magnetic resonance (MR) images reflects the destructive features of malignant gliomas. This study aimed to investigate the relationship between radiologic patterns of tumor enhancement, extent of resection, and prognosis in patients with anaplastic gliomas (AGs).

Methods

Clinical data from 268 patients with histologically confirmed AGs were retrospectively analyzed. Contrast enhancement patterns were classified based on preoperative T1-contrast MR images. Univariate and multivariate analyses were performed to evaluate the prognostic value of MR enhancement patterns on progression-free survival (PFS) and overall survival (OS).

Results

The pattern of tumor contrast enhancement was associated with the extent of surgical resection in AGs. A gross total resection was more likely to be achieved for AGs with focal enhancement than those with diffuse (p = 0.001) or ring-like (p = 0.024) enhancement. Additionally, patients with focal-enhanced AGs had a significantly longer PFS and OS than those with diffuse (log-rank, p = 0.025 and p = 0.031, respectively) or ring-like (log-rank, p = 0.008 and p = 0.011, respectively) enhanced AGs. Furthermore, multivariate analysis identified the pattern of tumor enhancement as a significant predictor of PFS (p = 0.016, hazard ratio [HR] = 1.485) and OS (p = 0.030, HR = 1.446).

Conclusion

Our results suggested that the contrast enhancement pattern on preoperative MR images was associated with the extent of resection and predictive of survival outcomes in AG patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat DeAngelis LM (2009) Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. J Clin Oncol 27:5861–5862CrossRefPubMed DeAngelis LM (2009) Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. J Clin Oncol 27:5861–5862CrossRefPubMed
2.
Zurück zum Zitat Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198CrossRefPubMed Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198CrossRefPubMed
3.
Zurück zum Zitat Nuno M, Birch K, Mukherjee D et al (2013) Survival and prognostic factors of anaplastic gliomas. Neurosurgery 73:458–465, quiz 465CrossRefPubMed Nuno M, Birch K, Mukherjee D et al (2013) Survival and prognostic factors of anaplastic gliomas. Neurosurgery 73:458–465, quiz 465CrossRefPubMed
4.
Zurück zum Zitat Shirai K, Suzuki Y, Okamoto M et al (2010) Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma. J Radiat Res 51:589–594CrossRefPubMed Shirai K, Suzuki Y, Okamoto M et al (2010) Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma. J Radiat Res 51:589–594CrossRefPubMed
5.
Zurück zum Zitat Hu LS, Eschbacher JM, Dueck AC et al (2012) Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 33:69–76CrossRefPubMed Hu LS, Eschbacher JM, Dueck AC et al (2012) Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 33:69–76CrossRefPubMed
6.
Zurück zum Zitat Jenkinson MD, du Plessis DG, Smith TS et al (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891CrossRefPubMed Jenkinson MD, du Plessis DG, Smith TS et al (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891CrossRefPubMed
7.
Zurück zum Zitat Mangla R, Ginat DT, Kamalian S et al (2014) Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol 116:325–331CrossRefPubMed Mangla R, Ginat DT, Kamalian S et al (2014) Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol 116:325–331CrossRefPubMed
8.
Zurück zum Zitat Megyesi JF, Kachur E, Lee DH et al (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303–4306CrossRefPubMed Megyesi JF, Kachur E, Lee DH et al (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303–4306CrossRefPubMed
9.
Zurück zum Zitat Tortosa A, Vinolas N, Villa S et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071CrossRefPubMed Tortosa A, Vinolas N, Villa S et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071CrossRefPubMed
10.
Zurück zum Zitat Chen C, Huang R, MacLean A et al (2013) Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 115:267–276CrossRefPubMed Chen C, Huang R, MacLean A et al (2013) Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 115:267–276CrossRefPubMed
11.
Zurück zum Zitat Keles GE, Chang EF, Lamborn KR et al (2006) Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 105:34–40CrossRefPubMed Keles GE, Chang EF, Lamborn KR et al (2006) Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 105:34–40CrossRefPubMed
12.
Zurück zum Zitat Sankar T, Moore NZ, Johnson J et al (2012) Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors. J Neurosurg 116:1172–1181CrossRefPubMed Sankar T, Moore NZ, Johnson J et al (2012) Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors. J Neurosurg 116:1172–1181CrossRefPubMed
13.
Zurück zum Zitat Nagy M, Schulz-Ertner D, Bischof M et al (2009) Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori 95:317–324PubMed Nagy M, Schulz-Ertner D, Bischof M et al (2009) Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori 95:317–324PubMed
14.
Zurück zum Zitat Nomiya T, Nemoto K, Kumabe T et al (2007) Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg 106:575–581CrossRefPubMed Nomiya T, Nemoto K, Kumabe T et al (2007) Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg 106:575–581CrossRefPubMed
15.
Zurück zum Zitat Scoccianti S, Magrini SM, Ricardi U et al (2012) Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro Oncol 14:798–807CrossRefPubMedPubMedCentral Scoccianti S, Magrini SM, Ricardi U et al (2012) Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro Oncol 14:798–807CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Schomas DA, Laack NN, Rao RD et al (2009) Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 11:437–445CrossRefPubMedPubMedCentral Schomas DA, Laack NN, Rao RD et al (2009) Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 11:437–445CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Hammoud MA, Sawaya R, Shi W et al (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65–73CrossRefPubMed Hammoud MA, Sawaya R, Shi W et al (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65–73CrossRefPubMed
18.
Zurück zum Zitat Sallinen PK, Sallinen SL, Helen PT et al (2000) Grading of diffusely infiltrating astrocytomas by quantitative histopathology, cell proliferation and image cytometric DNA analysis. Comparison of 133 tumours in the context of the WHO 1979 and WHO 1993 grading schemes. Neuropathol Appl Neurobiol 26:319–331CrossRefPubMed Sallinen PK, Sallinen SL, Helen PT et al (2000) Grading of diffusely infiltrating astrocytomas by quantitative histopathology, cell proliferation and image cytometric DNA analysis. Comparison of 133 tumours in the context of the WHO 1979 and WHO 1993 grading schemes. Neuropathol Appl Neurobiol 26:319–331CrossRefPubMed
19.
Zurück zum Zitat Gutman DA, Cooper LA, Hwang SN et al (2013) MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 267:560–569CrossRefPubMedPubMedCentral Gutman DA, Cooper LA, Hwang SN et al (2013) MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 267:560–569CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bradley D, Rees J (2014) Updates in the management of high-grade glioma. J Neurol 261:651–654CrossRefPubMed Bradley D, Rees J (2014) Updates in the management of high-grade glioma. J Neurol 261:651–654CrossRefPubMed
21.
Zurück zum Zitat Kim JW, Park CK, Park SH et al (2011) Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 82:224–227CrossRefPubMed Kim JW, Park CK, Park SH et al (2011) Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 82:224–227CrossRefPubMed
22.
Zurück zum Zitat Laigle-Donadey F, Martin-Duverneuil N, Lejeune J et al (2004) Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63:2360–2362CrossRefPubMed Laigle-Donadey F, Martin-Duverneuil N, Lejeune J et al (2004) Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63:2360–2362CrossRefPubMed
23.
Zurück zum Zitat Reyes-Botero G, Dehais C, Idbaih A et al (2014) Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 16:662–670CrossRefPubMedPubMedCentral Reyes-Botero G, Dehais C, Idbaih A et al (2014) Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 16:662–670CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Naeini KM, Pope WB, Cloughesy TF et al (2013) Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol 15:626–634CrossRefPubMedPubMedCentral Naeini KM, Pope WB, Cloughesy TF et al (2013) Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol 15:626–634CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173CrossRefPubMed Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173CrossRefPubMed
26.
Zurück zum Zitat Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Barboriak DP, MacFall JR, Viglianti BL et al (2008) Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. J Magn Reson Imaging 27:1388–1398CrossRefPubMedPubMedCentral Barboriak DP, MacFall JR, Viglianti BL et al (2008) Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. J Magn Reson Imaging 27:1388–1398CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Jackson A, Jayson GC, Li KL et al (2003) Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 76:153–162CrossRefPubMed Jackson A, Jayson GC, Li KL et al (2003) Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 76:153–162CrossRefPubMed
29.
Zurück zum Zitat Roberts HC, Roberts TP, Brasch RC et al (2000) Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 21:891–899PubMed Roberts HC, Roberts TP, Brasch RC et al (2000) Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 21:891–899PubMed
30.
Zurück zum Zitat Bae KT (2003) Peak contrast enhancement in CT and MR angiography: when does it occur and why? Pharmacokinetic study in a porcine model. Radiology 227:809–816CrossRefPubMed Bae KT (2003) Peak contrast enhancement in CT and MR angiography: when does it occur and why? Pharmacokinetic study in a porcine model. Radiology 227:809–816CrossRefPubMed
31.
Zurück zum Zitat Kubota T, Yamada K, Kizu O et al (2005) Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors. J Magn Reson Imaging 21:694–700CrossRefPubMed Kubota T, Yamada K, Kizu O et al (2005) Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors. J Magn Reson Imaging 21:694–700CrossRefPubMed
Metadaten
Titel
Identifying the association between contrast enhancement pattern, surgical resection, and prognosis in anaplastic glioma patients
verfasst von
Yinyan Wang
Kai Wang
Jiangfei Wang
Shaowu Li
Jun Ma
Jianping Dai
Tao Jiang
Publikationsdatum
21.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Neuroradiology / Ausgabe 4/2016
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI
https://doi.org/10.1007/s00234-016-1640-y

Weitere Artikel der Ausgabe 4/2016

Neuroradiology 4/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.